The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases

Prostate

Volumn 68, Issue 3, 2008, Pages 264-268

  Langsenlehner, Tanja ^a   Langsenlehner, Uwe ^a   Renner, Wilfried ^a   Kapp, Karin S ^a   Krippl, Peter ^b   Hofmann, Günter ^a   Clar, Heimo ^a   Pummer, Karl ^a   Mayer, Ramona ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Division of Internal Medicine   (Austria)

Author keywords

Apoptosis; Death receptor 4; Prognostic factors; Prostate cancer metastases; Single nucleotide polymorphisms

Indexed keywords

ALANINE; DEATH RECEPTOR 4; GLUTAMIC ACID; HORMONE; LIGAND; NUCLEASE;

AGED; ALLELE; ARTICLE; AUSTRIA; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; ENZYME ASSAY; FOLLOW UP; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LIGAND BINDING; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN POLYMORPHISM; RISK FACTOR;

AGED; AUSTRIA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA, NEOPLASM; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIGANDS; MALE; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 39449093139     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20682     Document Type: Article

References (20)

1. Baehrecke EH. How death shapes life during development. Nat Rev Mol Cell Biol 2002;3:779-787.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
3. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - Inducing signaling complex. Cell 1906; 85:817-827.
4. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821-830.
5. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7:831-836.
6. Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Grone HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Dohner H, Stilgenbauer S, Lichter P. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006;118:1831-1835.
7. Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 2004;109:661-667.
8. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res 2005;573:111-135.
9. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, Pummer K, Kapp KS. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: A population-based study. Eur J Cancer 2007;43:472-475.
10. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001;7:1688-1697.
11. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, Lee JH, Lee SK, Lee SN, Jung SS, Han JY, Kim H, Lee JY, Yoo NJ. Mutations of tumor necrosis factor-related apoptosis-inclucing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-4946.
12. Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim US, Ekman P. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate 2003;54: 103-111.
13. Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo M, Sagiyama K, Naito K. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 2001; 124:20-26.
14. Ries LAG, Melbert D, Krapeho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK, editors. 2007. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; http:// seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
15. Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, Daniel PT. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005;24:4052-4064.
16. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004;61:35-49.
17. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005;62:165-186.
18. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-5154.
19. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE. Targeting death receptors in bladder, prostate and renal cancer. J Urol 2006;175:432-438.
20. Li YC, Tzeng CC, Song JH, Tsia FJ, Hsieh LJ, Liao SJ, Tsai CH, Van Meir EG, Hao C, Lin CC. Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res 2006;12:2716-2729.